PASITHEA THERAPEUTICS CORP (KTTA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.52-1.89%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · KTTA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Dr. Krishnan will oversee all clinical development and medical strategy as the Company advances PAS-004 through the clinic for the treatment of neurofibromatosis type 1 (NF1) associated plexiform and…
Stated in a supplied disclosure. Management reported: “Dr. Krishnan will oversee all clinical development and medical strategy as the Company advances PAS-004 through the clinic for the treatment of neurofibromatosis type 1 (NF1) associated plexiform and cutaneous neurofibromas.” “The Company is currently testing PAS-004 in a Phase 1 clinical trial in patients with advanced cancer (NCT06299839), and a Phase 1/1b clinical trial in patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas with symptomatic and inoperable, incompletely resected, or recurrent PN (NCT06961565).”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Dr. Krishnan commented, “I am honored to join Pasithea at this point in the Company’s evolution, and excited for the opportunity to lead the development of PAS-004 in NF1 and potentially for other ra…
Stated in a supplied disclosure. Management reported: “Dr. Krishnan commented, “I am honored to join Pasithea at this point in the Company’s evolution, and excited for the opportunity to lead the development of PAS-004 in NF1 and potentially for other rare and pediatric diseases.” “Given my familiarity with the development of cobimetinib, I understand the broad potential of a safe, well-tolerated MEK inhibitor for NF1 patients and other rare and pediatric diseases.””
PAS-004 has demonstrated a differentiated pharmacokinetic (PK) profile that may hit the sweet spot between safety, tolerability and efficacy.
Stated in a supplied disclosure. Management reported: “PAS-004 has demonstrated a differentiated pharmacokinetic (PK) profile that may hit the sweet spot between safety, tolerability and efficacy.” “Given my familiarity with the development of cobimetinib, I understand the broad potential of a safe, well-tolerated MEK inhibitor for NF1 patients and other rare and pediatric diseases.””
Continue advancing PAS-004 clinical trials and medical strategy for NF1 and other indications.
Resolve Nasdaq listing deficiencies related to stock price to maintain listing status.
Over the trailing year it converted 1.01x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates, the US dollar (low R² over the window).
13 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.